WO2001081370A2 - Peptides derives d'histone h2a utiles dans la liberation de genes - Google Patents

Peptides derives d'histone h2a utiles dans la liberation de genes Download PDF

Info

Publication number
WO2001081370A2
WO2001081370A2 PCT/EP2001/004621 EP0104621W WO0181370A2 WO 2001081370 A2 WO2001081370 A2 WO 2001081370A2 EP 0104621 W EP0104621 W EP 0104621W WO 0181370 A2 WO0181370 A2 WO 0181370A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
complex
nucleic acid
cell
transfection
Prior art date
Application number
PCT/EP2001/004621
Other languages
English (en)
Other versions
WO2001081370A3 (fr
Inventor
Danuta Balicki
Ernest Beutler
Original Assignee
Novartis Ag
Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis-Erfindungen Verwaltungsgesellschaft M.B.H., The Scripps Research Institute filed Critical Novartis Ag
Priority to AU2001256319A priority Critical patent/AU2001256319A1/en
Priority to US10/258,637 priority patent/US20040102606A1/en
Priority to EP01929598A priority patent/EP1280822A2/fr
Publication of WO2001081370A2 publication Critical patent/WO2001081370A2/fr
Publication of WO2001081370A3 publication Critical patent/WO2001081370A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Abstract

La présente invention concerne un nouveau système de libération de gènes, dans lequel un peptide facilitant la libération de gènes, généralement dérivé d'histone H2A, est complexé avec un acide nucléique pour une libération efficace et stable dudit acide nucléique dans une cellule, et finalement vers le noyau. Ladite libération de gènes par peptides est basée sur le principe que des charges positives déneutralisées sur l'histone sont liées électrostatiquement par le squelette de phosphate de l'ADN chargé négativement et que les signaux de ciblage nucléaire dans les histones améliorent l'acheminement de l'ADN vers le noyau pour permettre la transcription.
PCT/EP2001/004621 2000-04-24 2001-04-24 Peptides derives d'histone h2a utiles dans la liberation de genes WO2001081370A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001256319A AU2001256319A1 (en) 2000-04-24 2001-04-24 Histone h2a-derived peptides useful in gene delivery
US10/258,637 US20040102606A1 (en) 2001-04-24 2001-04-24 Histone H2A -derived peptides useful in gene delivery
EP01929598A EP1280822A2 (fr) 2000-04-24 2001-04-24 Peptides derives d'histone h2a utiles dans la liberation de genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19915300P 2000-04-24 2000-04-24
US60/199,153 2000-04-24

Publications (2)

Publication Number Publication Date
WO2001081370A2 true WO2001081370A2 (fr) 2001-11-01
WO2001081370A3 WO2001081370A3 (fr) 2002-06-27

Family

ID=22736440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/004621 WO2001081370A2 (fr) 2000-04-24 2001-04-24 Peptides derives d'histone h2a utiles dans la liberation de genes

Country Status (3)

Country Link
EP (1) EP1280822A2 (fr)
AU (1) AU2001256319A1 (fr)
WO (1) WO2001081370A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030619A2 (fr) * 2005-09-08 2007-03-15 Nastech Pharmaceutical Company Inc. Compositions pharmaceutiques pour acheminer de l'acide ribonucleique dans une cellule
EP1793864A2 (fr) * 2004-09-27 2007-06-13 Nastech Pharmaceutical Company Inc. Methode de traitement de maladie inflammatoire par acide ribonucleique bicatenaire
WO2019219721A1 (fr) 2018-05-18 2019-11-21 F. Hoffmann-La Roche Ag Administration intracellulaire ciblée de grands acides nucléiques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014424A1 (fr) * 1994-11-08 1996-05-17 Medical Research Council Methode de transfert d'adn
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
WO1998040502A1 (fr) * 1997-03-14 1998-09-17 Life Technologies, Inc. Transfections activees par des peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100314721B1 (ko) * 1998-01-22 2001-11-23 김일웅 생물학적 활성이 있는 신규한 펩타이드

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014424A1 (fr) * 1994-11-08 1996-05-17 Medical Research Council Methode de transfert d'adn
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
WO1998040502A1 (fr) * 1997-03-14 1998-09-17 Life Technologies, Inc. Transfections activees par des peptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MILLER, CHARLEEN ET AL.: "SYNTHESIS PURIFICATION AND CHARACTERIZATION OF RAT HISTONE H2A (1-53)-NH2" retrieved from STN Database accession no. 115:227660 XP002195949 & ANAL CHIM ACTA (1991) 249(1) 215-25, *
KIM H S ET AL: "CDNA CLONING AND CHARACTERIZATION OF BUFORIN I, AN ANTIMICROBIAL PEPTIDE: A CLEAVAGE PRODUCT OF HISTONE H2A" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 229, 1996, pages 381-387, XP000941591 ISSN: 0006-291X *
PARK CHAN BAE ET AL: "Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 244, no. 1, 6 March 1998 (1998-03-06), pages 253-257, XP002195948 ISSN: 0006-291X *
See also references of EP1280822A2 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299236B2 (en) 2004-05-04 2012-10-30 Marina Biotech, Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP1793864A2 (fr) * 2004-09-27 2007-06-13 Nastech Pharmaceutical Company Inc. Methode de traitement de maladie inflammatoire par acide ribonucleique bicatenaire
EP1793864A4 (fr) * 2004-09-27 2010-09-22 Mdrna Inc Methode de traitement de maladie inflammatoire par acide ribonucleique bicatenaire
WO2007030619A2 (fr) * 2005-09-08 2007-03-15 Nastech Pharmaceutical Company Inc. Compositions pharmaceutiques pour acheminer de l'acide ribonucleique dans une cellule
WO2007030619A3 (fr) * 2005-09-08 2007-10-04 Nastech Pharm Co Compositions pharmaceutiques pour acheminer de l'acide ribonucleique dans une cellule
WO2019219721A1 (fr) 2018-05-18 2019-11-21 F. Hoffmann-La Roche Ag Administration intracellulaire ciblée de grands acides nucléiques

Also Published As

Publication number Publication date
AU2001256319A1 (en) 2001-11-07
EP1280822A2 (fr) 2003-02-05
WO2001081370A3 (fr) 2002-06-27

Similar Documents

Publication Publication Date Title
CN112266411B (zh) 一种新型冠状病毒疫苗及其应用
JP6766194B2 (ja) ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
EP1991560B1 (fr) Peptide présentant une activité de pénétration de membrane cellulaire
EP1966240B1 (fr) Peptides dérivés de la lactoferrine capables de péneétrer dans les cellules.
KR101590674B1 (ko) 세포-투과 펩티드 및 이의 용도
Smith et al. Synthetic peptide-based DNA complexes for nonviral gene delivery
AU2008296733B2 (en) VEGFR-1/NRP-1 targeting peptides
JP4697982B2 (ja) モジュラートランスフェクション系
JP2001503385A (ja) ポリヌクレオチド送達のための組成物および方法
KR20220044811A (ko) Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기
Medina-Kauwe et al. 3PO, a novel nonviral gene delivery system using engineered Ad5 penton proteins
US20040102606A1 (en) Histone H2A -derived peptides useful in gene delivery
CN110684798A (zh) 肌肉靶向的微环dna基因治疗
JP2002316997A (ja) 目的とするアニオン性物質を細胞に導入するための複合体
US6903077B1 (en) Methods and products for delivering nucleic acids
US20030044961A1 (en) Compositions for transferring active compounds in a cell-specific manner
EP1280822A2 (fr) Peptides derives d'histone h2a utiles dans la liberation de genes
KR20030022764A (ko) 원핵의 핵산 결합 단백질에 의한 분자 물질의 전달 방법
JP2022014707A (ja) キャリアペプチドフラグメントおよびその利用
WO2001096574A1 (fr) Nouveau gene enzymatique et son produit d'expression
Doan et al. Physical characteristics and stability profile of recombinant plasmid DNA within a film matrix
CN113061168B (zh) 一种截短的发热伴血小板减少综合征病毒Gn蛋白及其应用
US11834517B2 (en) Branched peptides for enzymatic assembly and mitochondria drug delivery
Balicki Gene transfer mediated by histone H2A
WO2013028527A1 (fr) Compositions et procédés pour traiter le cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001929598

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001929598

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10258637

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001929598

Country of ref document: EP